Perampanel is an antiepileptic medication approved for use in patients aged 12 years and older to manage partial-onset seizures with or without secondary generalization and primary generalized tonic-clonic seizures in epilepsy. It functions as a selective, non-competitive AMPA receptor antagonist, inhibiting the effects of glutamate, the primary excitatory neurotransmitter, thereby reducing excessive neuronal excitation and abnormal electrical activity in the brain to control and prevent seizures. Perampanel is typically prescribed as adjunctive therapy alongside other antiepileptic drugs, especially when monotherapy is insufficient. Treatment requires close monitoring by healthcare professionals due to potential side effects such as dizziness, somnolence, irritability, mood alterations, and behavioral changes. By providing effective seizure control, Perampanel plays a vital role in enhancing the quality of life for individuals with epilepsy.